Autolus Therapeutics (AUTL) Accumulated Depreciation & Amortization (2017 - 2025)
Autolus Therapeutics (AUTL) has disclosed Accumulated Depreciation & Amortization for 8 consecutive years, with $6.2 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Accumulated Depreciation & Amortization rose 9.13% year-over-year to $6.2 million, compared with a TTM value of $6.2 million through Sep 2025, up 9.13%, and an annual FY2024 reading of $7.6 million, up 15.06% over the prior year.
- Accumulated Depreciation & Amortization was $6.2 million for Q3 2025 at Autolus Therapeutics, up from $4.1 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $8.5 million in Q4 2021 and bottomed at $1.8 million in Q1 2024.
- Average Accumulated Depreciation & Amortization over 5 years is $4.9 million, with a median of $5.2 million recorded in 2023.
- The sharpest move saw Accumulated Depreciation & Amortization skyrocketed 49.49% in 2021, then dropped 17.03% in 2023.
- Year by year, Accumulated Depreciation & Amortization stood at $8.5 million in 2021, then dropped by 12.25% to $7.4 million in 2022, then fell by 11.55% to $6.6 million in 2023, then rose by 15.06% to $7.6 million in 2024, then dropped by 18.53% to $6.2 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for AUTL at $6.2 million in Q3 2025, $4.1 million in Q2 2025, and $2.0 million in Q1 2025.